Endocrine Abstracts

Introduction: Metastatic pituitary neuroendocrine tumors (PitNETs) or pituitary carcinomas are rare and challenging conditions. We present a recent and encouraging observation of a temozolomide (TMZ)-resistant clinically non-functioning metastatic PitNET showing a remarkable response to the anti-PDL1 drug Pembrolizumab.Case presentation: A 57-years-old man had transsphenoidal surgery in November 2012 for a large non-functioning intra/suprasellar mass rev...

Introduction: Hormone macromolecules are complexes of hormones with other compounds, most often with IgG immunoglobulin. They show variable immunoreactivity in immunochemical tests (IRMA, ELISA, CLIA, ECLIA) and usually have a weak biological effect. They can interfere with immunological assays of various hormones. Some known hormone macrocomplexes are: BB-PRL (24% - 34%), macro-TSH (0.6% - 1.2%) and very rare macromolecules of various hormones: calcitonin, PTH, insulin (singl...

Introduction: Emerging research in 3D-bone shape has provided new insights into the pathogenesis of osteoarthritis (OA). OA patients have increased subchondral bone area, associated with higher prevalence of cartilage loss. Higher B-score, a novel, machine learning-derived OA bone biomarker, is associated with increased OA symptom severity and structural progression. Arthropathy, despite being the commonest cause of morbidity amongst acromegaly patients, remains one of the und...

Introduction: Congenital hypogonadotropic hypogonadism (CHH) is a rare disease. Mutations in various genes have been implicated in its pathophysiology, the most frequent being ANOS1, FGFR1 and GNRHR genes. FGFR1 is essential for cell proliferation, differentiation and migration during embryonic development and is involved in GnRH neuron development and maintenance. Klotho-beta protein (KLB) is expressed in the postnatal hypothalamus and is t...

Purpose: We aimed to validate the diagnosis and estimated national incidence of acromegaly reported in the Swedish National Patient Register (NPR), based on clinically reported International Classification of Diseases (ICD-codes), in comparison with the Swedish Pituitary Register (SPR).Methods: All patients in NPR or SPR between 1991-2018 with the ICD-9 or ICD-10 diagnosis of acromegaly and age >18 years at diagnosis were included. The diagnosis was ...

Background: Diabetes is an important risk factor for cardiovascular morbidity and mortality but its impact on outcome in acromegaly is unknown.Methods: This was a nationwide, observational, matched-cohort study. Adult patients with acromegaly due to a pituitary adenoma were identified in the Swedish National Patient Registry between 1987 and 2020 and those with coexistent type 2 diabetes in the National Diabetes Registry and Drug Registry. Overall mortal...

Introduction: The aim of the present study was to explore pain prevalence, pain locations and its impact on everyday activities and health-related quality of life (QoL) in a large cohort of patients with acromegaly.Methods: We conducted a survey at three major centers specialized on the treatment of pituitary diseases. 124 patients with acromegaly (mean age 56.6y ± 13.5) filled in a self-constructed questionnaire on acromegaly symptoms, pain includi...

Background: Pasireotide is a second line treatment for acromegaly. Besides the growth hormone (GH) lowering efficacy, clinical use is limited by side effects on glycemic control. The aim of this study was to evaluate longitudinal changes in beta-cell function and insulin sensitivity induced by pasireotide therapy in patients with acromegaly.Methods: We performed a retrospective study in 33 patients. Efficacy (GH and IGF-I concentrations; tumor size) and ...